A phase III study of andexanet alfa as a reversal agent for edoxaban
Phase of Trial: Phase III
Latest Information Update: 06 May 2015
Price : $35 *
At a glance
- Drugs Andexanet alfa (Primary)
- Indications Haemorrhage
- Focus Registrational; Therapeutic Use
- Acronyms ANNEXA-E
- Sponsors Portola Pharmaceuticals
- 06 May 2015 According to a Portola Pharmaceuticals media release, final data from this and the other two phase III ANNEXA studies (see profiles 700242840 and 700238727) is expected to be presented in 2015.
- 12 Aug 2014 New trial record
- 06 Aug 2014 Portola Pharmaceuticals plans to initiate ANNEXA-E registration studies in 2015.